M. Peter Marinkovich

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M. Peter Marinkovich sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting early-phase tilt upper half by trial count

M. Peter Marinkovich: 2 sponsored US clinical trials, 1 recruiting.

M. Peter Marinkovich sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epidermolysis Bullosa Acquisita, with 1 trials.

Mid-pack sponsor footprint

M. Peter Marinkovich is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the M. Peter Marinkovich pipeline

1 recruiting of 2 indexed (50% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Epidermolysis Bullosa Acquisita (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

M. Peter Marinkovich: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

M. Peter Marinkovich sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share M. Peter Marinkovich1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
M. Peter Marinkovich sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

M. Peter Marinkovich sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this M. Peter Marinkovich page

2 registered trials is a research-attention snapshot, not an endorsement of M. Peter Marinkovich or any single study.

  • 1 of M. Peter Marinkovich's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Epidermolysis Bullosa Acquisita is the condition M. Peter Marinkovich studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epidermolysis Bullosa Acquisita trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

M. Peter Marinkovich pipeline card: 2 registered trials from official public datasets.Report a data error.